Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.

[1]  C. Gordon,et al.  Use of dual energy X-ray absorptiometry in pediatric patients. , 2017, Bone.

[2]  E. Rush,et al.  A retrospective review of initial bisphosphonate infusion in an inpatient vs. outpatient setting for bisphosphonate naïve patients , 2017, Journal of pediatric endocrinology & metabolism : JPEM.

[3]  L. Miladi,et al.  Lower incidence of fracture after IV bisphosphonates in girls with Rett syndrome and severe bone fragility , 2017, PloS one.

[4]  B. Wong,et al.  Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity , 2017, Neuromuscular Disorders.

[5]  L. Dimeglio,et al.  Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. , 2017, Bone.

[6]  F. Rauch,et al.  Osteogenesis imperfecta in children and adolescents—new developments in diagnosis and treatment , 2016, Osteoporosis International.

[7]  L. Ward,et al.  The management of osteoporosis in children , 2016, Osteoporosis International.

[8]  F. Glorieux,et al.  Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  P. Kaplan,et al.  Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience. , 2015, The Journal of clinical endocrinology and metabolism.

[10]  M. van Brussel,et al.  Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review , 2015, Hormone Research in Paediatrics.

[11]  G. Baroncelli,et al.  The Use of Bisphosphonates in Pediatrics , 2014, Hormone Research in Paediatrics.

[12]  S. Paul,et al.  Bisphosphonate Treatment for Children With Disabling Conditions , 2014, PM & R : the journal of injury, function, and rehabilitation.

[13]  C. Gordon,et al.  2013 Pediatric Position Development Conference: executive summary and reflections. , 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[14]  B. Zemel,et al.  Bone mineral content and density of the lumbar spine of infants and toddlers: Influence of age, sex, race, growth, and human milk feeding , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  J. Briody,et al.  Zoledronic acid improves bone mineral density in pediatric spinal cord injury , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  A. McCormick,et al.  The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy , 2012, Osteoporosis International.

[17]  T. Hangartner,et al.  Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. , 2011, The Journal of clinical endocrinology and metabolism.

[18]  R. McCall,et al.  Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. , 2011, The Journal of clinical endocrinology and metabolism.

[19]  D. Moher,et al.  Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders , 2010, Arthritis care & research.

[20]  B. Wong,et al.  The Relationship Between Fractures and DXA Measures of BMD in the Distal Femur of Children and Adolescents With Cerebral Palsy or Muscular Dystrophy , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  B. Zemel,et al.  Revised Pediatric Reference Data for the Lateral Distal Femur Measured by Hologic Discovery/Delphi Dual Energy X-Ray Absorptiometry , 2009, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[22]  C. V. Van Poznak,et al.  Significance and impact of bisphosphonate-induced acute phase responses , 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[23]  C. Cowell,et al.  Acute phase response and mineral status following low dose intravenous zoledronic acid in children. , 2007, Bone.

[24]  A. Wu.  Tietz clinical guide to laboratory tests. , 2006 .

[25]  H. Harcke,et al.  Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy. , 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[26]  Richard C. Henderson,et al.  Fracture rate in children with cerebral palsy , 2006, Pediatric rehabilitation.

[27]  D. Herndon,et al.  The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study , 2005, Osteoporosis International.

[28]  C. Anker,et al.  Cross-Sectional Study of Bone Mineral Density in Adult Survivors of Solid Pediatric Cancers , 2005, Journal of pediatric hematology/oncology.

[29]  P. Acott,et al.  Pamidronate treatment of pediatric fracture patients on chronic steroid therapy , 2005, Pediatric Nephrology.

[30]  L. Tatò,et al.  Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  H. Harcke,et al.  Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. , 2002, The Journal of pediatrics.

[32]  H. Harcke,et al.  Pediatric reference data for dual X-ray absorptiometric measures of normal bone density in the distal femur. , 2002, AJR. American journal of roentgenology.

[33]  M. Brandi,et al.  Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. , 2000, Arthritis and rheumatism.

[34]  D. Thiebaud,et al.  Effect of First Treatment with Aminobisphosphonates Pamidronate and Ibandronate on Circulating Lymphocyte Subpopulations , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  Crossen,et al.  Low-Dose Pamidronate Therapy for Pediatric Osteoporosis: Influence of Diagnosis on Changes in Fracture Rate and Bone Mineral Density , 2017 .

[36]  F. Glorieux,et al.  Osteogenesis imperfecta. , 2004, Lancet.